Phase 2, Multi-center, Open-label Trial to Evaluate Efficacy and Safety of GM-CT-01 in Combination With 5-FU as First Line Chemotherapy in Patients With Advanced Biliary Cancer.

Trial Profile

Phase 2, Multi-center, Open-label Trial to Evaluate Efficacy and Safety of GM-CT-01 in Combination With 5-FU as First Line Chemotherapy in Patients With Advanced Biliary Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Galactomannan C (Primary) ; Fluorouracil
  • Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
  • Focus Therapeutic Use
  • Sponsors Galectin Therapeutics
  • Most Recent Events

    • 31 Jul 2017 Status changed from discontinued to withdrawn prior to enrolment.
    • 09 Mar 2012 Actual patient number 17 added as reported by ClinicalTrials.gov.
    • 09 Mar 2012 Actual end date Jun 2009 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top